Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Meeting on the Mesa 2021 | Allogeneic NKX101 in liver cancer

Kanya Rajangam, MD, PhD, NKarta Therapeutics, South San Francisco, CA, discusses NKX101 in solid tumor indications. NKX101, an allogeneic NKG2D receptor chimeric antigen receptor (CAR) natural killer (NK) cell therapy, is currently being assessed in patients with relapsed/refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (MDS) in a Phase I trial (NCT04623944). In addition to AML and MDS, NKX101 use is being extended to liver localized tumors including hepatocellular carcinoma (HCC) and metastatic colorectal cancer. Transarterial delivery will enable successful trafficking of the cell therapy to the tumor by concentrating NKX101 in the tumor. This interview took place at Meeting on the Mesa 2021.